Orexo and Invida jointly announce agreement for Abstral™ in Asia Pacific

Orexo and Invida jointly announce agreement for Abstral™ in Asia Pacific

Alliance to Include Commercialization in 11 countries, including
Australia and India

Uppsala, Sweden and Singapore - January 14, 2010 - Orexo AB (STO: ORX)
and Invida Group Private Limited today announced the signing of an
exclusive licensing and distribution agreement, covering the Asia
Pacific region for Abstral™, Orexo's product for the treatment of
breakthrough cancer pain. Under the terms of the agreement, Orexo will
supply Invida with Abstral product, and Invida will be responsible for
all regulatory, medical, marketing and sales activities in eleven
countries across Asia Pacific, excluding China where the product is
already partnered. Financial terms of the agreement were not disclosed.

Thomas Lundqvist, acting CEO of Orexo said "Invida has a strong market
position in the region, and we firmly believe that the company will
effectively commercialize Abstral. Partner agreements are an important
source for generating additional profitability from Abstral on a global
basis”

John Graham, President and CEO of Invida added "This alliance will allow
us to leverage our suite of capabilities to meet the rapidly growing
demand for new, effective pain treatments in this region, and aligns
with our goal of forging true partnerships, in which we are able to
operate across the full value chain to bring pharmaceutical products
into the Asia Pacific markets.  Abstral represents a valuable asset to
enhance our growing oncology supportive care portfolio.  We are
extremely enthusiastic about the partnership and have great confidence
in the product and its performance throughout the region.”

This agreement extends to Australia, India, Philippines, South Korea,
Singapore, Indonesia, Malaysia, Taiwan, Thailand, Vietnam, and New
Zealand.

For further information please contact:
Orexo
Thomas Lundqvist, acting CEO
Tel: +46 (0)705 31 83 41
Email: thomas.lundqvist@orexo.com (thomas.lundqvist@orexo.com)

Robin Wright, EVP and CFO
Tel: +44 7720 300025
Email: robin.wright@orexo.com (robin.wright@orexo.com)

Invida
Media & Investors
Liz Pingpank
LaVoie Group
Tel: +1 978-745-4200 x104
Email: lpingpank@lavoiegroup.com (lpingpank@lavoiegroup.com)

About Abstral™
Abstral is a fast-acting and rapidly disintegrating sublingual tablet
formulation of fentanyl citrate designed for oral transmucosal delivery.
The product offers patients and clinicians a simple, patient friendly
and predictable way of delivering fentanyl transmucosally while
retaining the individualized dose titration aspects required for optimal
treatment of breakthrough pain.
Abstral was approved for marketing in the US in January 2011. ProStrakan
will launch Abstral in the US during Q1 2011. Abstral will be the only
fast-acting sublingual tablet for breakthrough cancer pain in the US
market. The overall annual market value in the US for fast-acting
fentanyl products is $550m (source: Wolters Kluwer, August 2010. MAT).
ProStrakan started sales of Abstral in Europe in 2009. During 2010,
sales amounted to GBP 17 million. By June 2010, the product had an
average share of 24% of the fast-acting fentanyl market across the five
largest European markets (source: IMS, June 2010).

About Breakthrough Cancer Pain
Breakthrough pain (“BTP”) is an acute and often severe flare of pain,
experienced by patients treated with round the clock opioid analgesics
for their underlying chronic cancer pain. It is known as breakthrough
pain because it "breaks through" a regular pain medicine schedule. For
some patients, breakthrough pain occurs during certain everyday
activities, such as walking or dressing. For others, it occurs
unexpectedly without any apparent cause.

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. Orexo is developing proprietary products based on
its proven reformulation technologies, targeted at the Specialty
Pharmaceutical market. Orexo intends to commercialize some of these
products itself in one or more major markets. Its development activity
builds on Orexo's core competences in R&D, which have previously
resulted in several successful products, currently out-licensed through
worldwide partnership agreements to larger pharmaceutical companies.
Today, Orexo has four products on the market of which Abstral® is a
leading product for the treatment of breakthrough pain in cancer
patients. Orexo also has three significant partnerships with major
pharmaceutical companies for research and development programs:
discovery stage collaborations with Ortho-McNeil Janssen and Janssen
Pharmaceutica in respiratory inflammation and with Boehringer Ingelheim
for inflammation and pain, both within the arachidonic acid cascade and
a clinical stage development agreement with Novartis for the treatment
of gastrointestinal disorders. Orexo's head office is located in
Uppsala, Sweden.
More information can be found at www.orexo.com (http://www.orexo.com/).

About Invida
Invida improves the lives of patients in Asia by commercializing
differentiated pharmaceutical products of superior quality - the result
of which will allow all Invida stakeholders to prosper. This is done
through proven brand marketing and sales know-how, strong expertise
across a number of key therapeutic categories and deep experience in all
critical Asian markets. Comprehensive functional capabilities provide
rapid market access delivered by passionate team of professionals.
With 4,000 employees in 13 markets in Asia Pacific, Invida operates
across the commercial value chain from regulatory approval and product
launch to lifecycle management. We manage a portfolio of proprietary
healthcare brands as well as licensed products from small biotech firms
and large multinational companies. Partnering is a critical component of
Invida's business model. We collaborate closely with our partners in
developing effective strategies and put our extensive experience behind
maximizing the potential of the assets entrusted to us.
More information can be found at
www.invida.com (https://connect.ne.cision.com/www.invida.com).

Note:
This is information that Orexo AB (publ.) is required to disclose
pursuant to the Swedish Securities Markets Act. The information was
provided for public release on January 14, 2011 at 08:00 a.m. CET.